BioMimetic Therapeutics, Inc. to Report Second Quarter 2012 Financial Results on August 2

BioMimetic Therapeutics, Inc. to Report Second Quarter 2012 Financial Results on August 2

BioMimetic Therapeutics, Inc.

[email protected]

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three and six months ended June 30, 2012, on Thursday, August 2 after the close of market. The Company will host a conference call and audio webcast to discuss its second quarter financial results, product development programs and business activities at 4:30 p.m. EDT the same day.

The conference call may be accessed on August 2, 2012 by dialing (877) 224 - 4059 for U.S. and Canadian callers (passcode:15383970). The international dial in number is (706) 902 - 2069, and the same passcode applies. Participants should dial in 10 minutes prior to the call.

A live webcast of the conference call will be available on the Investor Relations section of BioMimetic’s website at . The webcast will be archived for at least 30 days following the call.

BioMimetic Therapeutics (NASDAQ: BMTI) is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. All Augment branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.

BioMimetic has received regulatory approvals to market Augment Bone Graft in Canada, Australia and New Zealand for use in foot and ankle fusion indications. Augment is pending regulatory decisions in the U.S. and European Union for similar indications. The Company also markets a bone graft substitute line of products for orthopedic indications called Augmatrix Biocomposite Bone Graft.

For further information, contact Kearstin Patterson, senior director of corporate communications, at 615-236-4419.

Suggested Articles

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.